An expert clinical forum explores recent updates in the field and incorporating sotatercept treatment.
Back
Advances and Barriers in Pulmonary Arterial Hypertension Management
Highlights from a series of clinical forums spotlighting advances in pulmonary arterial hypertension (PAH) in 2026.
Advances and Barriers in Pulmonary Arterial Hypertension Management
Episodes
All
All
Panelists reached broad consensus that upfront dual oral combination therapy with an ERA and PDE5 inhibitor remains the foundational standard.
PAH specialists discuss prostacyclin use, pericardial effusion risks, erythrocytosis, and what real-world super-responders look like in practice.
Phoenix PAH specialists discuss RHC-guided monitoring, sotatercept shunting and erythrocytosis signals, meth-PAH management, and prostacyclin transition strategies.
Advertisement
Advertisement